.jpg "Matthew L. Zierhut, PhD, MBA photo")
Vice President
Certara Drug Development Solutions
Matt Zierhut has spent more than 14 years in the pharmaceutical industry, focusing on methodologies and applications of model-based meta-analysis (MBMA) for the past 10 years. He is motivated to provide value to clients by extracting insights from published clinical outcomes data using model-based techniques. This includes integrating modeling and simulation concepts into drug development strategy, with an emphasis on probability of success.
Prior to joining Certara in 2021, Matt led the development of Janssen’s global MBMA capability, working with multiple clinical development teams, across a variety of therapeutic areas, to ensure optimal impact of MBMA into program decision making. He also worked in the Pharmacometrics groups at both Pfizer and Amylin Pharmaceuticals, where he focused on a variety of projects, including preclinical-clinical translation, population PK and PK/PD modeling, drug-drug interaction, bioequivalence, and MBMA. Before working in the pharmaceutical industry, Matt spent time as a management consultant, which has encouraged him to emphasize the application of modeling and simulation, and how they can help improve internal decisions and regulatory interactions.
Matt holds degrees from U.C. Berkeley (B.S. in Electrical Engineering & Computer Science), University of Washington (M.S. in Bioengineering), U.C. Berkeley / U.C. San Francisco jointly (Ph.D. in Bioengineering), and U.C. Berkeley, Haas School of Business (MBA).
In his spare time, Matt enjoys spending time with his kids and family; going on camping adventures; playing volleyball; and relaxing whenever possible. He lives in San Diego, CA, with his wife and their four children.